Alan Bougen - Comvita Insider |
| CVNZF -- USA Stock | USD 3.97 0.00 0.00% |
Chairman
Mr. Alan John Bougen is no longer a NonExecutive Deputy Chairman of the Board of Comvita Limited., effective October 2017. He having been a foundation Director since 1976 and serving as Managing Director until 1998. His background in the natural healthcare industry, apiculture and international marketing, brings a particularly pertinent industry and global perspective to the Board as Comvita continues in the developments of its key offshore markets. Alan is a member of the Institute of Directors and operates his own consultancy business which includes directorships in other private companies.
64 7 533 1426 http://www.comvita.co.nz
Management Efficiency
The company has return on total asset (ROA) of 0.25 % which means that it generated profit of $0.25 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 6.64 % meaning that it generated $6.64 on every $100 dollars invested by stockholders.The company has accumulated 59.79 M in total debt with debt to equity ratio (D/E) of 46.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Comvita Limited has Current Ratio of 7.87 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Similar Executives
| Found 3 records | CHAIRMAN Since | |
| Eric Schmidt | Alphabet | 2018 |
| Roberto Sampedro | Ecopetrol S A | 2016 |
| Jeffrey Bezos | Amazon | 2000 |
Entity Summary
Comvita Limited manufactures and markets natural health products. Comvita Limited was founded in 1974 and is headquartered in Te Puke, New Zealand. Comvita operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market.Comvita Limited (CVNZF) is traded on OTC Market in USA. It is located in 23 Wilson Road South and employs 500 people.Comvita Limited Leadership Team
| Sarah Ottrey, Independent Director | |
| Simon Pothecary, Chief Sales Officer | |
| Ben Shaw, Chief Marketing Officer | |
| Paul Reid, Director | |
| Roy Ong, Chief Marketing Officer | |
| Patrick Brus, Chief Corporate Services Officer | |
| Alan Bougen, Non-Executive Deputy Chairman of the Board | |
| Maurice Prendergast, Independent Director | |
| Scott Coulter, Deputy CEO, COO | |
| Lucas Bunt, Independent Director | |
| Murray Denyer, Independent Director | |
| Sharon Hollenstein, Chief Innovation Officer | |
| Brett Hewlett, CEO | |
| Julianne Keast, Acting CFO | |
| Mark Sadd, Chief Commercial Officer | |
| Thomas Cullwick, Independent Director | |
| Neil Craig, Non-Executive Independent Chairman of the Board | |
| Kate Selway, Acting Chief People and Culture Officer | |
| Edward Quilty, Non-Executive Director | |
| RalfChristian Schlothauer, Chief Technical Officer | |
| MBA DipT, Chief Supply Chain Officer | |
| Sarah Kennedy, Independent Director | |
| Colin Baskin, Chief Supply Chain Officer | |
| Julie Chadwick, Corporate Communications Manager |
Stock Performance Indicators
| Shares Outstanding | 42.01 M |
Portfolio ReportingCreate custom reports across your portfolios and generate quick suggestion pitch |
| All Next | Launch Portfolio Reporting |
Pair Correlation
Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Comvita and Bristol Myers Squibb. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
| Run Pair Correlation |
Check also Trending Equities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.